Literature DB >> 1811420

Clinical characteristics of cholesteatoma.

B Aberg1, T Westin, A Tjellström, S Edström.   

Abstract

Clinical characteristics of 99 consecutive patients with acquired and perioperatively established aural cholesteatoma were compared with those of 81 patients with chronic otitis without cholesteatoma (controls). The patients answered a questionnaire, and preoperative and perioperative clinical observations were recorded. There were no presenting symptoms or clinical signs that significantly distinguished the cholesteatoma patients. However, these patients had a significantly higher incidence (45%) of previous middle ear surgery than the control patients (30%). The cholesteatomas were not evident until the time of surgical exploration in as many as 38% of cases. Therefore, surgical exploration appears to be the safest way to identify middle ear cholesteatoma.

Entities:  

Mesh:

Year:  1991        PMID: 1811420     DOI: 10.1016/0196-0709(91)90002-w

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  3 in total

1.  miR-199a Targeting PNRC1 to Promote Keratinocyte Proliferation and Invasion in Cholesteatoma.

Authors:  Lihui Yao; Wenjing Zhang; Jian Zheng; Xing Lu; Fan Zhang
Journal:  Biomed Res Int       Date:  2021-11-16       Impact factor: 3.411

2.  Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS.

Authors:  Matthias Schürmann; Johannes F W Greiner; Verena Volland-Thurn; Felix Oppel; Christian Kaltschmidt; Holger Sudhoff; Barbara Kaltschmidt
Journal:  Cells       Date:  2020-01-14       Impact factor: 6.600

3.  Characteristics of 419 patients with acquired middle ear cholesteatoma.

Authors:  Letícia Petersen Schmidt Rosito; Maurício Noschang Lopes da Silva; Fábio André Selaimen; Yuri Petermann Jung; Marcos Guilherme Tibes Pauletti; Larissa Petermann Jung; Luiza Alexi Freitas; Sady Selaimen da Costa
Journal:  Braz J Otorhinolaryngol       Date:  2016-05-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.